Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Dec 19 2025

Dec 19, 2025 at 9:49 AM EST · Issued by Zydus Lifesciences Limited

Filed with NSE · Dec 19, 2025 at 9:49 AM EST · 4 pages · English

On 6ix: 6ix.com/news/press-release-dec-19-2025-3

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 19, 2025, titled "Zydus Lifesciences Limited signs an exclusive agreement with Myriad Genetics of US to launch cancer-risk assessment diagnostic tests in India".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Press Release Dec 15 2025Dec 15, 2025
Press Release Dec 10 2025Dec 10, 2025
Press Release Dec 09 2025Dec 9, 2025
Zydus and Formycon enter into an Exclusive Partnership for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab), in US and CanadaDec 9, 2025
Press Release Dec 04 2025Dec 4, 2025

Later from Zydus Lifesciences

Zydus Partners with Bioeq for U.S. Commercialisation rights for NUFYMCO®, an Interchangeable Biosimilar to Lucentis®Dec 23, 2025
Press Release Dec 23 2025Dec 23, 2025
Zydus Partners with Bioeq for U.S. Commercialisation rights for NUFYMCO(R), an Interchangeable Biosimilar to Lucentis(R)Dec 24, 2025
Zydus Lifesciences Limited Press Release Jan 13 2026Jan 12
Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S.Jan 15

All Zydus Lifesciences news releases

Follow Zydus Lifesciences into a list and get an email when it puts out news.

Follow Zydus Lifesciences